It was shown in a previous communication (Crawhall et al., 1963) that the abnormally high level of cystine excretion found in homozygotes for cystinuria could be reduced for short periods by the administration of D-penicillamine. This paper reports the results of administering the drug continuously to a group of cystinuric patients for periods of five months to one year.
We have used the D-isomer of penicillamine rather than the racemic (DL) mixture because L-penicillamine antagonizes pyridoxal phosphate and is known to be toxic in experimental animals (Aposhian and Aposhian, 1959) . Continuous treatment with D-penicillamine has-been used in other diseases, and no serious toxic effects have been reported. Rash, fever, lymphadenopathy, and leucopenia sometimes occur soon after the beginning of treatment but can be overcome by the administration of anti-inflammatory steroids for short periods (Scheinberg and Sternlieb, 1960) . Goldberg et al. (1963) reported proteinuria in a patient with chronic lead-poisoning who was treated with D-penicillamine, and Walshe (1960) observed that a patient who was allergic to penicillin was abnormally sensitive to penicillamine. Levine (1960) noted cutaneous cross-sensitivity reactions to penicillin, benzylpenicilloic acid, and penicillamine.
We have previously reported chromatographic evidence for the presence of L-cysteine-D-penicillamine in the urine of cystinuric patients taking D-penicillamine (Crawhall et al., 1963) . This substance has now been synthesized and purified. Its solubility properties have been studied, and it has been shown to be identical with the new disulphide which appears in the urine of cystinuric patients taking D-penicillamine.
Methods and Materials
The methods of gravimetric and paper chromatographic analysis of cystinuric urine have been previously described (Crawhall et al., 1963 Synthesis of L-cysteine-D-penicillamine Mixed Disulphide.-L-cysteine hydrochloride (1.5 g., 9.6 mmole) and D-penicillamine hydrochloride (330 mg., 1.8 mmole) were dissolved in ammonium Case 2.-A woman aged 39 had had eight episodes of renal colic, the first of which occurred when she was 13 years old. Four of these had required admission to hospital. She had a left ureterolithotomy and right pyelolithotomy when she was 23 and a right ureterolithotomy at the age of 25. There was no family history of renal disease, and she excreted about 700 mg. of cystine per 24 hours before treatment was begun. Headache, sore throat, malaise, mild fever, and a generalized irritant morbilliform rash developed on the ninth day of treatment with D-penicillamine. The eruption progressed to a mild exfoliative phase despite the use of promethazine hydrochloride (25 mg. eight-hourly), and a mild eosinophilia was observed. There was no previous history of abnormal sensitivity to drugs or other agents. Penicillamine treatment was discontinued and we did not attempt to reinstate it. The excretion of L-cysteine-D-penicillamine mixed disulphide and D-penicillamine disulphide continued for two days after the administration of D-penicillamine was stopped.
Case 3.-A man aged 29 had previously been a merchant seaman in the tropics and had had repeated episodes of calculus formation for 13 years. These were initially right-sided, and a right nephrec-tomy had been performed seven years previously. smelling urine. Three patients developed a reaction to the drug on about the ninth day of treatment. No specific therapy was used in Case 2, but in subsequent cases the side-effects were suppressed by a short course of corticosteroid therapy and no further ill-effects were observed. The duration of prolonged therapy ranges from five months to one year (Table II) . Urine analyses have been carried out at intervals during that period, and there is no evidence that the effects of the drug diminish with time. No proteinuria has developed, and the peripheral blood picture has remained normal. The intensity of the cystine spot on filter-paper chromatograms of the patients' urine decreased and two new spots appeared during D-penicillamine therapy as previously described (Crawhall et al., 1963) . The area of a chromatogram bearing the presumed L-Cysteine-D-penicillamine disulphide was cut out, the amino-acid eluted with hydrochloric acid (approximately iN), and the eluant removed by evaporation. The residue was oxidized with performic acid (Hirs, 1956) , and the products were identical with authentic cysteic and penicillaminic acid as judged by the filter-paper chromatography.
A chromatogram prepared from a cystinuric patient's urine to which the mixed disulphide and penicillamine disulphide had been added was identical with chromatograms prepared from the same patient's urine when she was subsequently treated with D-penicillamine, except for the presence of cystine in the former case.
Ion-exchange chromatography with the Technicon automatic amino-acid analyser confirmed that D-penidillamine therapy was associated with a considerable reduction in cystine excretion, and the excretion of two new compounds whose peak effluent volumes corresponded to those of L-cysteine-Dpenicillamine mixed disulphide and D-penicillamine disulphide respectively. The excretion of lysine, arginine, and ornithine was unaltered by D-penicillamine administration. In this method of analysis acidified urine is applied direct to the ionexchange column and the amino-acids are eluted at pH 2.87. The high concentration of hydrogen ions eliminates the theoretical possibility that disulphide exchange might occur during the analysis.
Discussion
The determination of cystine in the presence of other disulphides presents special problems. Thus, although the urinary cystine can be measured by isotope dilution analysis, polarography (Fowler et al., 1952) , ion-exchange chromatography (Brigham et al., 1960) , and colorimetric analysis-for example, Hess and Sullivan (1935) when the patient is not taking penicillamine, a gravimetric procedure has proved most suitable for routine use during treatment (see Table I ). The gravimetric results are confirmed by isotope dilution analysis using [35S] 
Clinical Features
With the exception of two staff and two girls under 12, all the cases occurred in the 12-17 age-group, affecting chiefly girls aged 13-16. The rash was confined to the hands and fingers in 67%, to the feet and toes in 8%, and in 25% it was on both hands and feet. It occurred mainly on the backs of the fingers and toes but also on the fronts of the fingers, the hands, the borders of the feet, and the heels. In most girls the rash comprised between 5 and 10 lesions, but in some there were up to 50.
The lesions were between 0.5 and 3 cm. in diameter, raised, and dark red to purple in colour with some surrounding bluish erythema. Vesicles appeared in the centre in many and reached a size of 0.5-1 cm. in diameter (Figs. 1-3) . Particularly on the fronts of the fingers and hands, the vesicles developed a grey flaccid appearance. Some of the lesions ulcerated. There was slight itching, and some were painful and tender, and where
